ProPhase Labs, Inc. (PRPH)
| Market Cap | 171.52K -99.1% |
| Revenue (ttm) | 3.85M -31.2% |
| Net Income | -22.46M |
| EPS | -1.71 |
| Shares Out | 15.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,196 |
| Open | 0.0100 |
| Previous Close | 0.00973 |
| Day's Range | 0.0100 - 0.0120 |
| 52-Week Range | 0.0090 - 6.6590 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About ProPhase Labs
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, inc... [Read more]
Financial Performance
In 2025, ProPhase Labs's revenue was $4.35 million, a decrease of -35.82% compared to the previous year's $6.77 million. Losses were -$14.74 million, -72.37% less than in 2024.
Financial StatementsNews
ProPhase Labs Quarterly report: Q2 2026
ProPhase Labs has published its Q2 2026 quarterly earnings report on August 19, 2026.
ProPhase Labs Quarterly report: Q1 2026
ProPhase Labs has published its Q1 2026 quarterly earnings report on June 30, 2026.
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform
$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potentia...
ProPhase Labs Earnings release: Q4 2025
ProPhase Labs released its Q4 2025 earnings on April 15, 2026, summarizing the period's financial results.
ProPhase Labs Annual report: Q4 2025
ProPhase Labs has published its Q4 2025 annual report on April 15, 2026.
ProPhase Labs says Crown Medical Collections effort ‘continues to advance’
ProPhase Labs (PRPH) provided a business update regarding its Crown Medical Collections initiative and related strategic activities. The Company reported that its Crown Medical Collections effort cont...
ProPhase Labs Slides: Investor presentation
ProPhase Labs has posted slides in relation to its latest quarterly earnings report, which was published on February 20, 2026.
ProPhase Labs initiates potential sale, partnership for BE-Smart
ProPhase Labs (PRPH) announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated esophageal cancer risk stratification test, and is advanci...
ProPhase Labs provides Crown Medical Collections update
ProPhase Labs (PRPH) provided an operational update on the progress of its Crown Medical Collections initiative relating to legacy COVID-19 testing receivables held by its laboratory subsidiaries curr...
ProPhase Labs uplists from Pink Sheets to OTC Market
ProPhase Labs (PRPH) announced that its common stock has been approved and uplisted from the Pink Sheets to the OTC market.
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value
UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company's un...
ProPhase Labs trading halted, news pending
19:50 EST ProPhase Labs (PRPH) trading halted, news pending
ProPhase Labs Transcript: Status Update
A merger LOI with ABL aims to unlock synergies in diagnostics, with current shareholders retaining valuable Crown Medical receivables and up to $10 million from new capital. Key assets—Crown Medical, BE-Smart, and Nebula Genomics—are positioned for significant growth, with a positive outlook for 2026.
ProPhase Labs Press release: Status Update
ProPhase Labs issued a press release on December 19, 2025, disclosing material business information to investors.
ProPhase Labs Slides: Status Update
ProPhase Labs has posted slides in relation to its latest quarterly earnings report, which was published on December 19, 2025.
Why Is Prophase Labs Stock (PRPH) Up Today?
Prophase Labs stock saw a massive rally on Friday alongside its plans for a reverse merger.
ProPhase Labs signs non-binding LOI for proposed reverse merger with ABL
ProPhase Labs (PRPH) and Advanced Biological Laboratories entered into a non-binding Letter of Intent regarding a proposed reverse merger transaction pursuant to which ABL would become the majority ow...
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.
ProPhase Labs Slides: Investor Presentation
ProPhase Labs has posted slides in relation to its latest quarterly earnings report, which was published on December 2, 2025.
ProPhase Labs Transcript: Status Update
Crown Medical Collections is expected to deliver over $50 million in near-term cash, supporting a turnaround after significant cost reductions and asset restructuring. The company is ready to commercialize its BE-Smart cancer test and expand its genomics business, with multiple financing and M&A options under consideration.
ProPhase Labs Press release: Status Update
ProPhase Labs issued a press release on December 1, 2025, disclosing material business information to investors.
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by Red...
ProPhase Labs Earnings Call Transcript: Q3 2025
Management expects significant cash inflows from Crown Medical Collections and is exploring multiple strategic deals, including M&A and partnerships, to unlock value. The BE-Smart Esophageal Cancer Test and Nebula Genomics are positioned for growth, with a focus on maintaining Nasdaq compliance.
ProPhase Labs Earnings release: Q3 2025
ProPhase Labs released its Q3 2025 earnings on November 19, 2025, summarizing the period's financial results.
ProPhase Labs Quarterly report: Q3 2025
ProPhase Labs has published its Q3 2025 quarterly earnings report on November 19, 2025.